Merck collaborates with angiex to speed clinical readiness of new cancer therapy
Merck, a leading science and technology company, today announced a new collaboration with Angiex, Inc., Cambridge, Massachusetts, USA to support the biotechnology start-up's ability to speed its lead oncology antibody drug candidate to clinical use. Angiex is developing an antibodydrug conjugate (ADC) therapy for cancer against a vascular target, TM4SF1.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Merck | Pharmaceuticals | Science